A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 9, 2015, Pages 1669-1678

  Okuma, Yusuke ^a   Tanuma, Junko ^b   Kamiryo, Hiroshi ^c   Kojima, Yuki ^d   Yotsumoto, Mihoko ^e   Ajisawa, Atsushi ^a   Uehira, Tomoko ^c   Nagai, Hirokazu ^d   Takeda, Yuichiro ^b   Setoguchi, Yasuhiro ^e   Okada, Seiji ^f  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^e TOKYO MEDICAL UNIVERSITY   (Japan)

^f KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Epidermal growth factor receptor mutation; Highly active antiretroviral therapy; Human immunodeficiency virus; Lung cancer; Non AIDS defining cancer

Indexed keywords

ANTIRETROVIRUS AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL FEATURE; ETHNIC DIFFERENCE; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; JAPAN; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; MOLECULAR EPIDEMIOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; CLINICAL TRIAL; FAR EAST; GENETICS; HIV INFECTIONS; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; FAR EAST; FEMALE; HIV INFECTIONS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84939269690     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1956-8     Document Type: Article

References (58)

1. Alshafie MT, Donaldson B, Oluwole SF (1997) Human immunodeficiency virus and lung cancer. Br J Surg 84:1068–1071
2. Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I (2014) Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 25(10):1935–1940
3. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27(36):6251–6266
4. Bertolaccini L, Lybéris P, Soncini S, Giovanni D, Emilpaolo M (2008) Clinical characteristic lung cancer in HIV-infected patients. Cancer Ther 6:903–906
5. Bower M, Powles T, Nelson M, Shah P, Cox S, Mandelia S, Gazzard B (2003) HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 17(3):371–375
6. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465
7. Brock MV, Hooker CM, Engels EA, Moore RD, Gillison ML, Alberg AJ, Keruly JC, Yang SC, Heitmiller RF, Baylin SB, Herman JG, Brahmer JR (2006) Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 43(1):47–55
8. Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA (2007) Elevated risk of lung cancer among people with AIDS. AIDS 21(2):207–213
9. Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4(5):336–347
10. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374(9699):1432–1440
11. Clifford GM, Lise M, Franceschi S, Egger M, Bouchardy C, Korol D, Levi F, Ess S, Jundt G, Wandeler G, Fehr J, Schmid P, Battegay M, Bernasconi E, Cavassini M, Calmy A, Keiser O, Schoni-Affolter F, Swiss HIVCS (2012) Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer 106(3):447–452
12. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Agan BK, Wegner S (2009) Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 23(1):41–50
13. Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intrieri T, Vercelli M, Zambon P, Tagliabue G, Zanetti R, Federico M, Limina RM, Mangone L, De Lisi V, Stracci F, Ferretti S, Piffer S, Budroni M, Donato A, Giacomin A, Bellu F, Fusco M, Madeddu A, Vitarelli S, Tessandori R, Tumino R, Suligoi B, Franceschi S, Cancer, Study ARL (2009) Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 100(5):840–847
14. D’Jaen GA, Pantanowitz L, Bower M, Buskin S, Neil N, Greco EM, Cooley TP, Henry D, Stem J, Dezube BJ, Stebbing J, Aboulafia DM (2010) Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer 11(6):396–404
15. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ, Study HACM (2006) Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 20(12):1645–1654
16. Engsig FN, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Gerstoft J, Obel N (2011) Lung cancer in HIV patients and their parents: a Danish cohort study. BMC Cancer 11:272
17. Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT, Gerard L, Oksenhendler E (2007) Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood 110(8):2846–2854
18. Grubb JR, Moorman AC, Baker RK, Masur H (2006) The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS 20(8):1095–1107
19. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, Le Marchand L (2006) Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 354(4):333–342
20. Hakimian R, Fang H, Thomas L, Edelman MJ (2007) Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol 2(4):268–272
21. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, Crane HM, Willig J, Mugavero M, Saag M, Martin JN, Deeks SG (2009) Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 48(6):787–794
22. Lanoy E, Spano JP, Bonnet F, Guiguet M, Boue F, Cadranel J, Carcelain G, Couderc LJ, Frange P, Girard PM, Oksenhendler E, Poizot-Martin I, Semaille C, Agut H, Katlama C, Costagliola D (2011) The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer 129(2):467–475
23. Lavole A, Chouaid C, Baudrin L, Wislez M, Raguin G, Pialoux G, Girard PM, Milleron B, Cadranel J (2009) Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer 65(3):345–350
24. Levine AM, Seaberg EC, Hessol NA, Preston-Martin S, Silver S, Cohen MH, Anastos K, Minkoff H, Orenstein J, Dominguez G, Watts DH (2010) HIV as a risk factor for lung cancer in women: data from the Women’s Interagency HIV study. J Clin Oncol 28(9):1514–1519
25. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388
26. Makinson A, Pujol JL, Le Moing V, Peyriere H, Reynes J (2010) Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer. J Thorac Oncol 5(4):562–571
27. Massera F, Rocco G, Rossi G, Robustellini M, Pona CD, Meroni A, Rizzi A (2000) Pulmonary resection for lung cancer in HIV-positive patients with low (<200 lymphocytes/mm(3)) CD4(+) count. Lung Cancer 29(2):147–149
28. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, West Japan Oncology Group (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128
29. Nakanjako D, Kiragga A, Ibrahim F, Castelnuovo B, Kamya MR, Easterbrook PJ (2008) Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance. AIDS Res Ther 5:23
30. Natinal-Lung-Screening-Trial (2010) National Lung Screening Trial (NLST) Initial Results: Fast Facts. http://www.cancergov/newscenter/pressreleases/2011/NLSTFastFacts
31. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311(7010):899–909
32. Okuma Y, Yanagisawa N, Takagi Y, Hosomi Y, Suganuma A, Imamura A, Iguchi M, Okamura T, Ajisawa A, Shibuya M (2012) Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infection. Int J Clin Oncol 17(5):462–469
33. Okuma Y, Yanagisawa N, Hosomi Y, Imamura A, Okamura T, Kato K, Negishi K (2013) Concomitant chemoradiotherapy and antiretroviral therapy for HIV-infected patients with locoregionally advanced non-small cell lung cancer: benefit and tolerability of treatment in 2 cases. Onkologie 36(10):586–590
34. Oriol A, Ribera JM, Esteve J, Sanz MA, Brunet S, Garcia-Boyero R, Fernandez-Abellan P, Marti JM, Abella E, Sanchez-Delgado M, Penarrubia MJ, Besalduch J, Moreno MJ, Borrego D, Feliu E, Ortega JJ, Pethema Group SSoH (2003) Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica 88(4):445–453
35. Oriol A, Ribera JM, Brunet S, del Potro E, Abella E, Esteve J (2005) Highly active antiretroviral therapy and outcome of AIDS-related Burkitt’s lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica 90(7):990–992
36. Ou SH, Ziogas A, Zell JA (2009) Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 4(9):1083–1093
37. Pakkala S, Ramalingam SS (2010) Lung cancer in HIV-positive patients. J Thorac Oncol 5(11):1864–1871
38. Pakkala S, Chen Z, Rimland D, Owonikoko TK, Gunthel C, Brandes JR, Saba NR, Shin DM, Curran WJ Jr, Khuri FR, Ramalingam SS (2012) Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer 118(1):164–172
39. Petoumenos K, Hui E, Kumarasamy N, Kerr SJ, Choi JY, Chen YM, Merati T, Zhang F, Lim PL, Sungkanuparph S, Pujari S, Ponnampalavanar S, Ditangco R, Lee CK, Grulich A, Law MG, Database TAHO (2010) Cancers in the TREAT Asia HIV Observational Database (TAHOD): a retrospective analysis of risk factors. J Int AIDS Soc 13(1):51
40. Rengan R, Mitra N, Liao K, Armstrong K, Vachani A (2012) Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol 13(12):1203–1209
41. Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA (2015) Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst 107(4):dju503. doi:10.1093/jnci/dju503
42. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sanchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M, Spanish Lung Cancer G (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958–967
43. Samet JM, Wiggins CL, Humble CG, Pathak DR (1988) Cigarette smoking and lung cancer in New Mexico. Am Rev Respir Dis 137(5):1110–1113
44. Sanchez X, Cousins-Hodges B, Aguilar T, Gosselink P, Lu Z, Navarro J (1997) Activation of HIV-1 coreceptor (CXCR4) mediates myelosuppression. J Biol Chem 272(44):27529–27531
45. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550
46. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT, Centers for Disease Control and Prevention (2008) Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years–United States, 2008. MMWR Recomm Rep 57(RR-10):1–12
47. Setiawan VW, Haiman CA, Stanczyk FZ, Le Marchand L, Henderson BE (2006) Racial/ethnic differences in postmenopausal endogenous hormones: the multiethnic cohort study. Cancer Epidemiol Biomark Prev 15(10):1849–1855
48. Sigel K, Crothers K, Dubrow R, Krauskopf K, Jao J, Sigel C, Moskowitz A, Wisnivesky J (2013) Prognosis in HIV-infected patients with non-small cell lung cancer. Br J Cancer 109(7):1974–1980
49. Spano JP, Massiani MA, Bentata M, Rixe O, Friard S, Bossi P, Rouges F, Katlama C, Breau JL, Morere JF, Khayat D, Couderc LJ (2004) Lung cancer in patients with HIV Infection and review of the literature. Med Oncol 21(2):109–115
50. Spitsin S, Tustin NB, Riedel E, Tustin R III, Murray JB, Peck LM, Khan M, Quinn J, Douglas SD (2012) Programmed death 1 receptor changes ex vivo in HIV-infected adults following initiation of highly active antiretroviral therapy. Clin Vaccine Immunol 19(5):752–756
51. Sridhar KS, Flores MR, Raub WA Jr, Saldana M (1992) Lung cancer in patients with human immunodeficiency virus infection compared with historic control subjects. Chest 102(6):1704–1708
52. Tirelli U, Spina M, Sandri S, Serraino D, Gobitti C, Fasan M, Sinicco A, Garavelli P, Ridolfo AL, Vaccher E (2000) Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer 88(3):563–569
53. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454
54. UNAIDS (2012) 2012 UNAIDS report on the global AIDS epidemic: http://www.unaids.org/en/resources/publications/2012/name,76121,en.asp
55. Vyzula R, Remick SC (1996) Lung cancer in patients with HIV-infection. Lung Cancer 15(3):325–339
56. Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, Goy A, Hedrick E, Zelenetz AD, Noy A (2003) Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 98(6):1196–1205
57. White CS, Haramati LB, Elder KH, Karp J, Belani CP (1995) Carcinoma of the lung in HIV-positive patients: findings on chest radiographs and CT scans. AJR Am J Roentgenol 164(3):593–597
58. Wistuba II, Behrens C, Milchgrub S, Virmani AK, Jagirdar J, Thomas B, Ioachim HL, Litzky LA, Brambilla EM, Minna JD, Gazdar AF (1998) Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA 279(19):1554–1559